The efficacy and toxicity of FOLFOX regimen (a combination of leucovorin and fluorouracil with oxaliplatin) as first-line treatment of metastatic colorectal cancer

Japanese Journal of Cancer and Chemotherapy

Volumn 36, Issue 5, 2009, Pages 797-801

  Matsushita, Hidenobu ^a   Tsuboi, Kenji ^a   Honda, Ichiro ^a   Kato, Nobuyuki ^a   Okochi, Osamu ^a   Kobayashi, Daisuke ^a   Hattori, Masashi ^a  

^a TOSEI GENERAL HOSPITAL   (Japan)

Author keywords

First line; FOLFOX; Metastatic colorectal cancer; Oxaliplatin

Indexed keywords

FLUOROURACIL; FOLINIC ACID; OXALIPLATIN;

ANOREXIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL EVALUATION; COLORECTAL CANCER; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; HUMAN; LEUKOPENIA; METASTASIS; NAUSEA; NEUTROPENIA; RETROSPECTIVE STUDY; SENSORY NEUROPATHY; SURVIVAL TIME; TREATMENT RESPONSE;

EID: 79959816843     PISSN: 03850684     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Vital Statistics of Japan. Statistics and Information Dept. Minister's Secretariat, Ministry of Health, Labour and Welfare. Health and Welfare Statistics Association. Tokyo, 2006.
2. Glimelius B, Hoffman K, Graf W, et al: Quality of life during chemotherapy in patients with symptomatic advanced colorectal cancer. The Nordic Gastrointestinal Tumor Adjuvant Therapy Group. Cancer 73: 556-562, 1994. (Pubitemid 24046593)
3. Advanced Colorectal Cancer Meta-Analysis Project: Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer. Evidence in terms of response rate. J Clin Oncol 10: 896-903, 1992.
4. Cunningham D, Pyrhönen S, James RD, et al: Randomized trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 352: 1413-1418, 1998.
5. Rougier P, Van Custem E, Bajetta E, et al: Randomized trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 352: 1407-1412, 1998. (Pubitemid 28510873)
6. Saltz LB, Cox JV, Blanke C, et al: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 343: 905-914, 2000.
7. Douillard JY, Cunningham D, Roth AD, et al: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicenter randomized trial. Lancet 355: 1041-1047, 2000. (Pubitemid 30162806)
8. De Gramont A, Figer A, Seymour M, et al: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18: 2938-2947, 2000. (Pubitemid 30644117)
9. Goldberg RM, Morton RF, Sargent DJ, et al: N9741: oxaliplatin or CPT-11 plus 5-fluorouracil/leucovorin or oxaliplatin plus CPT-11 in advanced colorectal cancer. Updated efficacy and quality of life data from an intergroup study. Proc Am Soc Clin Oncol 22:252, 2003 (abstr 1009).
10. Raymond E, Buquet-Fagot C, Djelloul S, et al: Antitumor activity of oxaliplatin in combination with 5-fluorouracil and the thymidylate synthase inhibitor AG337 in human colon, breast, and ovarian cancers. Anticancer Drugs 8: 876-885, 1997. (Pubitemid 27487802)
11. National Comprehensive Cancer Network: NCCN Clinical Practice Guidelines in Oncology, Colon Cancer - Version 2. 2006 Available from: http://www.nccn.org/ professionals/physician-gls/f-guidelines.asp?button=I+Agree
12. National Comprehensive Cancer Network: NCCN Clinical Practice Guidelines in Oncology, Rectal Cancer - Version 2. 2006 Available from:http://www.nccn.org/ professionals/physician-gls/f-guidelines.asp?button=I+Agree
13. Becouarn Y, Ychou M, Ducreux M, et al: Phase II trial of oxaliplatin as first-line chemotherapy in metastatic colorectal cancer patients. J Clin Oncol 16: 2739-2744, 1998. (Pubitemid 28363039)
14. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92: 205-216, 2000. (Pubitemid 30099779)
15. Kaplan EL and Meier P: Nonparametric estimation from incomplete observations. Amer Stat Assoc J 53: 457-481, 1958.
16. Cassidy J, Misset JL: Oxaliplatin-related side effects: characteristics and management. Semin Oncol 29: 11-20, 2002.
17. Hochster HS, Grothey A and Childs BH: Use of calcium and magnesium salts to reduce oxaliplatin-related neurotoxicity. J Clin Oncol 25: 4028-4029, 2007. (Pubitemid 47477294)
18. Goldberg RM, Sargent DJ, Alberts SR, et al: A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 22: 23-30, 2004. (Pubitemid 41095110)
19. Rothenberg ML, Oza AM, Bigerow RH, et al: Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial. J Clin Oncol 21: 2059-2069, 2003. (Pubitemid 46606353)
20. Tournigand C, Andre T, de Gramont A, et al: FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 22: 229-237, 2004. (Pubitemid 41095086)